FindTrial
Sign In

Randomized controlled clinical study of antiviral therapy for children with chronic hepatitis B immune tolerant phase.

Randomized controlled clinical study of antiviral therapy for children with chronic hepatitis B immune tolerant phase.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004684
Enrollment
Unknown
Registered
2014-05-22
Start date
2014-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

therapy:IFNa
Control:IFNa

Sponsors

302 Military Hospital of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 16 Years

Inclusion criteria

Inclusion criteria: 1 ~ 16 years old children hospitalized for HBeAg positive chronic hepatitis B, the guardian's consent and / or voluntary basis after full communication and signed the informed consent were included in the study. All children must also comply with serum HBsAg positive for at least 6 months; the alanine aminotransferase (ALT) levels were normal or slightly elevated (ALT < 1.5ULN), HBeAg, HBVDNA positive, HBeAb negative liver pathology; ? suggestive of liver inflammation in G = 1; ? before entering the group June have not received interferon, nucleoside or nucleoside analogue antiviral treatment; the serum HIV, HCV, except HDV seropositive patients. Diagnostic criteria in line with the "Chinese prevention and treatment of chronic hepatitis B guide" (2010 Edition) standard.

Exclusion criteria

Exclusion criteria: not meet the entry requirements

Design outcomes

Primary

MeasureTime frame
HBeAg;ALT;HBVDN;—

Countries

China

Contacts

Public ContactZhu Shishu
302zss@sina.com+86 133666861032

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026